Philadelphia, USA-based biotech company discovering and developing more effective drugs by testing them on lab-grown human organs, Vivodyne raised USD 38 million in seed funding. The round took place on November 22, 2023. Khosla Ventures led the financing for the company. Meanwhile, Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures joined in the funding.
Purpose of financing for Vivodyne
With the latest seed round proceeds, the company seeks to advance Vivodyne’s discovery pipeline. It also has plans to fund the expansion of a clinically predictive AI stack, which identifies novel therapeutic targets and predicts patient responses to new drugs by testing directly on lab-grown human organ tissues.
What the company’s official has to comment
Andrei Georgescu, CEO and Co-Founder of Vivodyne said, “We’re thrilled to have Khosla Ventures lead this funding round, which accelerates the development of our AI platform that enables the generation of predictive human data before therapeutics enter clinical trials. By combining the principles of organoids and organs-on-chips, we’ve created a new class of lifelike, lab-grown human organs. We use these lab-grown human test subjects to discover and develop new therapies for human diseases. The result is huge amounts of complex human data—larger than you could get from any clinical trial—and we train multimodal models on this data to predict and improve the safety and efficacy of new drugs. This breakthrough not only enhances the predictive accuracy of AI in drug development but also promises to significantly improve the success rates of AI-generated drugs, setting a new standard in the field.”
In addition, Susan Billings, Chief Commercial Officer of Vivodyne, said, “The next frontier of therapeutics development rests on achieving greater preclinical certainty before drugs enter clinical trials. Biopharma companies face a pivotal challenge when years of research and significant financial investment confront the unpredictability of clinical trial outcomes, and it doesn’t have to be a nailbiter waiting for those results in the eleventh hour. This is biotech’s biggest challenge and our critical focus. Our platform enables the collection of invaluable human data from early discovery to post-approval — faster, at a larger scale, with far more human predictability than animal studies. By producing human data from the outset, we’re identifying and validating novel targets and significantly mitigating risk prior to clinical trials. For approved therapies, we’re expanding their impact through the discovery of new indications and enhancing patient care.”
What the investors have to comment
Alex Morgan, Partner at Khosla Ventures, said, “By testing drugs and lifesaving biologics directly on these realistic human tissues at an unprecedented scale and resolution, we can improve the success rates of therapeutics entering clinical trials. Vivodyne’s technology bridges the gap between preclinical R&D and human clinical trials while automating every step of the testing pipeline, from growing tissues, dosing, sampling and imaging to analyzing data. The ability to screen and develop new potential lifesaving therapies, testing thousands at a time on functionally realistic human tissues on Vivodyne’s automated platform, is a major step forward for the pharmaceutical industry.”
Besides, Alex Andrianopoulos, Chief R&D Officer at Kairos Ventures, said, “What truly sets Vivodyne apart is the seamless integration of lifelike, functional lab-grown human tissues, best-in-class robotics, and a strong AI stack — which comes together with the singular focus of generating vast volumes of predictive, preclinical human data. The most important aspect is how these pieces all converge to produce huge quantities of predictive, preclinical human data that Vivodyne’s AI pipelines can harness to create better and safer drugs more quickly.”
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!Next Article
